Antiplatelet Therapy in Older Patients Post-Myocardial Infarction

2022 ◽  
Vol 37 (1) ◽  
pp. 17-23
Author(s):  
Hindu Rao ◽  
Paul Phan ◽  
Megan Eclevia ◽  
Laura Tsu
Keyword(s):  
Myocardial Infarction ◽  
Adverse Effects ◽  
Older Patients ◽  
Treatment Options ◽  
Antiplatelet Agents ◽  
Post Myocardial Infarction ◽  
Older Patient ◽  
Antiplatelet Treatment ◽  
Specific Factors

This case study reviews appropriate antiplatelet treatment options for an older patient post-myocardial infarction and stent placement. This case investigates the benefits and risks associated with antiplatelet agents in older people and what patient- and drug-specific factors, such as adverse effects and drug interactions, to consider when choosing treatment.

Clots Kill: Hematologic Pharmacology for ST-Segment Elevation Myocardial Infarction

2012 ◽  
Vol 32 (6) ◽  
pp. 35-41
Author(s):  
Stacy H. James
Keyword(s):  
Myocardial Infarction ◽  
Acute Coronary Syndrome ◽  
Antiplatelet Agents ◽  
Thrombin Inhibitors ◽  
Fibrinolytic Agents ◽  
St Segment Elevation ◽  
Coronary Syndrome ◽  
Segment Elevation Myocardial Infarction ◽  
St Segment

Drugs that work on the hematologic system play an important role in helping to limit the morbidity and mortality that can be associated with an acute coronary syndrome. The pharmacology of the fibrinolytic agents, thrombin inhibitors, and antiplatelet agents is described. A case study of a woman having an ST-segment elevation myocardial infarction is reviewed to highlight the importance of drugs that work on the hematologic system.

Mineralocorticoid receptor antagonists

ESC CardioMed ◽  
2018 ◽  
pp. 167-173
Author(s):  
Faiez Zannad ◽  
João Pedro Ferreira
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Adverse Effects ◽  
Beneficial Effect ◽  
Mechanism Of Action ◽  
Mineralocorticoid Receptor ◽  
Post Myocardial Infarction ◽  
Mineralocorticoid Receptor Antagonists ◽  
Receptor Antagonists ◽  
Clinical Syndromes

Hypertension, post-myocardial infarction, and heart failure are the cardiovascular clinical syndromes where mineralocorticoid receptor antagonists (MRAs) have shown a beneficial effect. Most guidelines while recommending a MRA do not make a clear recommendation as to which MRA should be used, how doses should be titrated, or which monitorization is indicated. This chapter provides an appraisal of the different types of MRA drugs and their pharmacological differences with respect to mechanism of action, pharmacokinetics, monitoring, adverse effects, and drug interactions.

scholarly journals Post-myocardial infarction ventricular septal defect. Is it better to operate on a fresh infarction or to wait? A case study

2016 ◽  
Vol 1 ◽  
pp. 39-41
Author(s):  
Bogdan Suder ◽  
Łukasz Janik ◽  
Grzegorz Wasilewski ◽  
Janusz Konstanty-Kalandyk ◽  
Jerzy Sadowski ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Ventricular Septal Defect ◽  
Septal Defect ◽  
Post Myocardial Infarction

scholarly journals How I treat the older patient with acute myeloid leukemia

Blood ◽  
2015 ◽  
Vol 125 (5) ◽  
pp. 767-774 ◽  
Author(s):  
Gert Ossenkoppele ◽  
Bob Löwenberg
Keyword(s):  
Acute Myeloid Leukemia ◽  
Older Patients ◽  
Myeloid Leukemia ◽  
Treatment Options ◽  
Comorbid Conditions ◽  
Older Patient ◽  
Molecular Features ◽  
Clinical Vignettes ◽  
Clinical Biology ◽  
Acute Myeloid

Abstract Acute myeloid leukemia (AML) in older patients presents a notable therapeutic challenge to the clinical hematologist. The clinical biology of AML among patients is highly heterogeneous. Interpatient variations are relevant for prognosis and treatment choice. Outcome of treatment for patients of advanced age is often compromised by comorbid conditions and an enhanced susceptibility to toxicities from therapy. Here we present selected clinical vignettes that highlight distinct representative situations derived from clinical practice. The vignettes are specifically discussed in light of the perspective of treating older patients with leukemia. We review the clinical significance of various cytogenetic and molecular features of the disease, and we examine the various currently available treatment options as well as the emerging prognostic algorithms that may offer guidance in regard to personalized therapy recommendations. The dilemmas in tailoring treatment selection in this category of patients with AML are the central theme in this discussion.

Sign in / Sign up

Export Citation Format

Share Document